Metagenomi Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Net Income	-68.26	-43.59	-21.44
Depreciation & Amortization	8.41	3.03	1.32
Share-Based Compensation	6.92	1.96	0.38
Other Operating Activities	-38.49	68.33	44
Operating Cash Flow	-91.41	29.72	24.26
Operating Cash Flow Growth	-	22.54%	-
Capital Expenditures	-9.81	-13.98	-2.9
Change in Investments	55.55	-108.22	-71.41
Investing Cash Flow	45.73	-122.2	-74.32
Share Issuance / Repurchase	-3.28	0	0
Debt Issued / Paid	0	0	29.97
Other Financing Activities	4.3	239.59	9.95
Financing Cash Flow	1.01	239.59	39.92
Net Cash Flow	-44.66	147.12	-10.14
Free Cash Flow	-101.22	15.75	21.35
Free Cash Flow Growth	-	-26.26%	-
Free Cash Flow Margin	-226.17%	91.55%	8787.65%
Free Cash Flow Per Share	-29.73	4.63	6.55

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).